elevidys gene therapy - Search News

Order byBest matchMost fresh

News

Sarepta Reports 2nd Death of Patient on Its Gene Therapy

DMD Gene Therapy Elevidys Suspended After Second Patient Death

Following a second patient death, Sarepta is temporarily suspending use of Elevidys in non-ambulatory DMD patients, pending evaluation of an enhanced immunosuppression regimen.

Continue reading

· 1d · on MSN

Second patient death reported with gene therapy for muscular dystrophy

· 1d · on MSN

Sarepta Stock Plunges After Death of Second Patient Receiving Its Gene Therapy

Managed Healthcare Executive1d

Sarepta Stops Shipments of Elevidys For Non-Ambulatory DMD Patients

A second patient with Duchenne muscular dystrophy has died from acute liver failure after receiving the gene therapy Elevidys ...

1d

Sarepta Therapeutics Stock Plummets Over 40% On Second Fatal Case Linked To Its Gene Therapy

Sarepta suspends Elevidys use in non-ambulatory Duchenne patients after two liver failure deaths, triggering FDA review and ...

1don MSN

Sarepta crashes after second death linked to Roche-partnered Elevidys

Sarepta Therapeutics ( NASDAQ: SRPT) fell ~38% in the premarket on Monday after the company reported a second fatality from ...

3d

Sarepta Provides Safety Update for ELEVIDYS and Initiates Steps to Strengthen Safety in Non-Ambulatory Individuals with Duchenne

Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today provided a safety ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results